DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy Volunteers

Information source: National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Monoclonal B-Cell Lymphocytosis

Phase: N/A

Status: Recruiting

Sponsored by: National Heart, Lung, and Blood Institute (NHLBI)

Official(s) and/or principal investigator(s):
Clare C Sun, M.D., Principal Investigator, Affiliation: National Heart, Lung, and Blood Institute (NHLBI)

Overall contact:
Clare C Sun, M.D., Phone: (301) 451-7130, Email: clare.sun@nih.gov

Summary

Background:

- Chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell

lymphoma (MCL) are types of cancers in which there are too many abnormal lymphocytes (a type of white blood cell). Monoclonal B-cell lymphocytosis (MBL) is a condition in which the individual has a larger than normal number of lymphocytes. Individuals with CLL, SLL, MBL, and MCL may survive for many years without the need for treatment, but there is an apparent correlation between cell birth rates and disease activity. By studying the birth and death rates of lymphocytes, researchers hope to identify individuals who are at risk for worsening disease.

- Heavy water is similar in structure to regular water, but it has two deuterium atoms

instead of two hydrogen atoms. Deuterium has one more neutron than hydrogen, which is what makes heavy water heavy. Heavy water is not radioactive, looks and tastes like regular water, and has no known harmful effects at research-level doses. When a small amount of heavy water is consumed daily, newly produced blood cells are labeled (tagged), which allows researchers to track cell growth and to measure the birth and death rates of CLL, SLL, MBL, MCL or normal lymphocytes. Objectives:

- To study the birth and death rates of lymphocytes from individuals with MBL, CLL/SLL, and

MCL, compared with lymphocytes from healthy volunteers. Eligibility:

- Individuals at least 18 years of age who have been diagnosed with MBL, CLL, SLL, or

MCL, but who have not been taking certain agents (Viagra, Levitra, Cialis, or other PDE-inhibitors, prednisone, cyclosporin-A, rapamycin, or other immunosuppressive agents, more than 2 cups of green tea daily, or Celebrex) for 4 weeks prior to enrollment in the study.

- Healthy volunteers at least 18 years of age, but who have not been taking certain

agents (Viagra, Levitra, Cialis, or other PDE-inhibitors, prednisone, cyclosporin-A, rapamycin, or other immunosuppressive agents, more than 2 cups of green tea daily, or Celebrex)for 4 weeks prior to enrollment in the study. Design:

- Participants will be screened with a medical history, physical examination, and initial

blood tests. Other tests may be administered to the individuals with cancer, as required by the study researchers.

- All participants will drink regular doses of heavy water daily for a total of 4 weeks

(labeling period). There is an optional 6-month follow-up or wash-out period during which no additional heavy water will be consumed.

- Blood samples will be collected weekly during the labeling period, and a bone marrow

biopsy will be obtained where possible. Individuals with cancer may also have a lymph node biopsy during this part of the study.

- Additional blood samples may be collected during the optional wash-out phase of

the study to determine the rate at which cancer cells disappear.

- Treatment is not provided as part of this protocol.

Clinical Details

Official title: A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy Volunteers.

Study design: Time Perspective: Prospective

Primary outcome: To estimate the cell proilferation rate of tumor cells in individuals with MBL, CLL/SLL, and MCL.

Secondary outcome: Proliferation rate in tissue compared to blood, disappearance rate of labeled cells from the blood and tissue and the safety profile of heavy water in the study population/

Detailed description: Chronic lymphocytic leukemia (CLL) and its lymphoma variant, small lymphocytic lymphoma (SLL) were for decades considered diseases caused by the progressive accumulation of abnormal lymphocytes. The prevailing view being that CLL and SLL disease processes were driven by an underlying defect in apoptosis. While resistance to apoptosis appears to be important in the CLL and SLL disease process, recent studies suggest that cellular proliferation is more important than previously realized. Cells from individuals with CLL who drank deuterated water (heavy water) for 6 weeks showed a turnover rate of 0. 1 % to 1. 1 % per day. In a second study involving CLL subjects who drank heavy water, average CLL turnover rates were in a similar range but approximately 2-fold lower than average B-cell turnover rates from healthy individuals. These studies have shown the safety and scientific value of using heavy water to study the kinetics of cell proliferation in patients and normal volunteers. We now propose this study to expand on findings by other investigators. This study will address the site of proliferation for CLL/SLL cells and will include individuals with monoclonal B-cell lymphocytosis (MBL), a possible precursor of CLL. Furthermore, we will include patients with mantle cell lymphoma (MCL), a disease in which tumor proliferation plays an important role. Study participants will drink heavy water daily for a total of 4 weeks (labeling period) with an optional 6 months follow up ( wash out period). Blood samples will be obtained weekly during the labeling period. A bone marrow and/or lymph node biopsy will be obtained where possible during the labeling period. Additional blood draws may be obtained during the optional wash-out phase of the study to determine the rate at which tumor cells disappear. The primary objective of this exploratory study is to obtain an estimate of the proliferation rate of tumor cells in individuals with MBL, CLL/SLL, and MCL. The secondary objectives are to compare proliferation rates between different anatomic compartments, specifically peripheral blood, lymph node, and bone marrow and the estimation of the attrition or disappearance rate of cells during an optional phase of the protocol. Healthy volunteers may be included for comparison.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

- INCLUSION CRITERIA: (MBL, CLL/SLL, MCL group)

4. 1.1.< TAB> Diagnosed with MBL, CLL/SLL, or MCL 4. 1.2.< TAB> Greater than or equal to 18 years of age 4. 1.3.< TAB> Neutrophil count (ANC) greater than or equal to 1000/mcL 4. 1.4.< TAB> Platelet count greater than or equal to 50K/mcL EXCLUSION CRITERIA: (MBL, CLL/SLL, MCL group) 4. 2.1.< TAB> Concomitant use of agents that have been described to affect the biology and/or proliferation rate of CLL cells but are not approved or accepted therapies for CLL, SLL, MCL, or MBL

- PDE-inhibitors (e. g. sildenafil, theophylline)

- Immunosuppressive agents (e. g., prednisone, cyclosporin-A, rapamycin)

- Green Tea extract (more than 2 cups per day)

- Cox-2 inhibitors

4. 2.2.< TAB> Chronic or current clinically significant infection, including HIV or uncontrolled infection 4. 2.3.< TAB> Receiving concurrent anticancer therapies 4. 2.4.< TAB> Women who are pregnant or nursing, as well as women of childbearing potential who are unwilling to use a an agreed upon form of contraception for the duration of participation in this study 4. 2.5< TAB> Sexually active males who are unwilling to follow the strict contraception requirements described in this protocol. 4. 2.6< TAB> Inability to understand the investigational nature of the study, inability to provide informed consent INCLUSION CRITERIA: (Healthy volunteer group) 4. 3.1< TAB> Health status will be confirmed by brief History and Physical Exam and blood work 4. 3.2< TAB> Greater than or equal to 18 years of age 4. 3.3< TAB> CBC and coagulation panel within the expected normal ranges for the subject EXCLUSION CRITERIA: (Healthy volunteer group) 4. 4.1.< TAB> Concomitant use of agents that have been described to affect the biology and/or proliferation rate of CLL cells

- PDE-inhibitors (e. g. , slidenafil, theophylline)

- Immunosuppressive agents (e. g., cyclosporin-A, rapamycin)

- Green Tea extract (more than 2 cups per day)

- Cox-2 inhibitors

< TAB> 4. 4.2.< TAB> Women who are pregnant or nursing, as well as women of childbearing potential who are unwilling to use an agreed upon form of contraception for the duration of study participation. 4. 4.3< TAB> Sexually active males who are unwilling to follow the strict contraception requirements described in this protocol. 4. 4.4.< TAB> Inability to understand the investigational nature of the study, inability to provide informed consent

Locations and Contacts

Clare C Sun, M.D., Phone: (301) 451-7130, Email: clare.sun@nih.gov

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland 20892, United States; Recruiting
For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL), Phone: 800-411-1222, Ext: TTY8664111010, Email: prpl@mail.cc.nih.gov
Additional Information

NIH Clinical Center Detailed Web Page

Related publications:

Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood. 1998 Jan 1;91(1):3-21. Review.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. doi: 10.3322/caac.20006. Epub 2009 May 27.

Redaelli A, Laskin BL, Stephens JM, Botteman MF, Pashos CL. A systematic literature review of the clinical and epidemiological burden of acute lymphoblastic leukaemia (ALL). Eur J Cancer Care (Engl). 2005 Mar;14(1):53-62. Review.

Starting date: April 2010
Last updated: August 7, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017